- Reaction score
- 614
What above statements demonstrate that the drug doesn't get deeper into the body when it's applied topically?
They say, "Its metabolite has substantially reduced AR agonist activity in vivo, thereby limiting its side effects."
Maybe it's me, but I don't understand how the fact that the "metabolite substantially reduces AR agonist activity in vivo" means that it doesn't get deeper into a person's body. Can anyone here help me with this?
It's not about it not going systemic, it's that it's somewhat inert once it does